Tammy McDaid’s 5-Year-Old Son Tate Has Childhood Dementia. A Newly Approved U.S. Gene Therapy Could Stop It, and It Costs About $3.95 Million.
Tate Flaherty is 5 years old, nonverbal, and, in his mother’s words, “a ball of joy.” He also has Sanfilippo syndrome Type A, a rare genetic disease often called childhood dementia, which slowly takes away the skills a child has already learned. His mother, Tammy McDaid, 34, of Swansea, Wales, told Talker News that a gene therapy approved in the United States could stop the damage, but the price is about £2.95 million, or roughly $3.95 million.
She is now racing to raise the money before the disease takes more of him.
A diagnosis that took years to land
McDaid first took Tate to a doctor when he was 2. He rarely cried, and she wondered whether he might be autistic. Doctors noticed a bump on his head, and an MRI raised the possibility of Sanfilippo syndrome. About a year later, she was told he didn’t have it.
She wasn’t convinced. McDaid had seen children on TikTok who looked like her son, and she kept pushing for more tests. In September 2025, Tate was officially diagnosed with Sanfilippo syndrome Type A. He is also autistic and has never spoken.
“It got denied last August, and Tate officially got diagnosed in September,” McDaid said, describing a treatment request that was turned down in August 2025, just before the diagnosis was confirmed.
Tate is now showing early signs of cognitive decline, according to the Talker News report.
What childhood dementia does to a child
Sanfilippo syndrome is the common name for mucopolysaccharidosis type III, or MPS III. According to MedlinePlus, run by the U.S. National Library of Medicine, it mainly affects the brain and spinal cord. Children usually seem healthy at birth, then show signs in early childhood: speech delays, hyperactivity, sleep problems and, over time, the loss of skills they once had. Seizures and trouble moving can come later.
Type A, Tate’s form, is caused by changes in the SGSH gene, and MedlinePlus says it tends to start earlier and move faster than the other types. All four types together affect about 1 in 70,000 newborns. A child has to inherit an altered copy of the gene from each parent.
“A lot of the children pass away before their 10th birthday,” McDaid said.
The therapy, and its price
The treatment McDaid is chasing is called UX111. On Sept. 17, 2026, its maker, Ultragenyx, announced FDA approval of the therapy under the brand name Fayuvi. The company called it the first FDA-approved treatment for Sanfilippo syndrome Type A.
Fayuvi is a one-time IV infusion that delivers a working copy of the SGSH gene. It is approved for children with Type A whose brain development is still preserved, which is why timing matters so much for families like Tate’s. Ultragenyx said children treated in its trial scored 23.5 points higher on a cognitive test between 24 and 60 months of age than untreated children followed in a natural history study.
The therapy does not reverse symptoms that have already appeared. As Talker News put it, it should stop further brain damage. Tate would need to travel to the United States for a blood test and then the treatment itself.
Ultragenyx did not list a price in its approval announcement. McDaid said the company plans to charge £2.95 million per child through insurance, and the family, paying on their own, is in talks about whether the cost could be different for them.
McDaid said she is praying the company will lower the price for families who pay for the treatment themselves.
A fundraiser run by a children’s charity
The appeal, called “Saving Tate,” is hosted on JustGiving and run by Just4Children, a registered UK charity. The page sets a target of £3,050,000: an estimated £2.95 million for the treatment and £100,000 for related costs. As of Nov. 17, it showed more than £223,000 in online donations, plus about £44,600 in Gift Aid.
The page says the money would go toward Fayuvi or another treatment Tate’s doctors recommend. If that treatment becomes unavailable, the funds would pay for his ongoing care.
Other families have walked a similar road. Eliza O’Neill’s parents raised $2 million when she was small to fund a gene therapy for Sanfilippo syndrome, and she was nearly 17 when the FDA approved the gene therapy she had waited for. In Canada, Zorawar Chandi’s parents have raised nearly $1.4 million toward a $5 million gene therapy for a different rare disease.
A mother living on hope
McDaid told Talker News that learning a treatment existed brought on what she called a “happy panic attack.” She said she has spent the year living on hope, fundraising and doing whatever she can for her son.
For now, she describes a little boy who doesn’t seem to notice the weight around him. “A very happy one, because he’s just so blasé with life,” she said. What she wants is simple to say and hard to buy: the chance that “Tate can actually celebrate his 18th birthday,” which she called “like a dream.”
Get stories like this by email. Sign up for The Parent Diaries Letter.
This article was produced with AI assistance and edited for accuracy against the sources linked above.
Image: John Lord – CC BY-SA 2.0/Wikimedia Commons
